– Eurostars projects targets the development of new, close to the market products, processes and services and their access to transnational and international markets in all fields.
Rondol Technology Ltd designs and manufactures a portfolio of polymer processing equipment suitable for Micro/Nano Applications (mixing, extrusion, moulding, compression). Rondol was founded in 2001 by former directors of Prism Consultants, which was earlier acquired by Thermo Haake.
The range of polymer processing equipment was developed until 2005 with European investors joining in 2007. This accelerated the company's commercial and technical development, which has continued to produce new and innovative design solutions. At the German Plastics Fair (Kunststoff 2007) Rondol successfully exhibited their Microlab, the world's smallest commercial twin screw extruder (10mm diameter) with touch screen PC based control. This resulted in the development of sales to top universities, research centers and industrial customers. In September 2012 Rondol opended a new R&D site in Strasbourg.
The new site will especially focus on Research and Development for the Pharmaceutical and Food Industries and also house the global marketing and sales department. For this purpose Strasbourg is equipped with a new Rondol 40:1 L/D 10mm Twin Screw Extrusion line in its full GMP Pharma-layout of all stainless steel surfaces and contact parts as well as various feeding and downstream devices.
CorTec, Thinking ahead to innovate neurotechnology in Freiburg.
CorTec is developing a neurotechnological implant for measuring and stimulating brain activity. This system works in a closed loop: It is able to control the stimulation internally via feedback from the brain itself. So it will adapt its further activities to the actual need for treatment. Responsive systems of this kind are the future of neurotechnology.
The technology designed by CorTec allows the brain to communicate with the outside world and the outside world to interact with the brain. It offers many fields of application in therapy, rehabilitation or assistive technology. Chronic Pain for example can be treated via cortex stimulation; paralyzed people can learn to control assistive devices by the power of thought. In addition, the technology can address many other indications.
CorTec is located in Freiburg im Breisgau, Germany. Founded in 2010, the young medtech company has made some important progresses. The first product, a foil electrode for measuring and stimulating brain activity on short term, is about entering the market. In clinical setting it is used as a diagnostic tool for the invasive treatment of epilepsy and brain tumors. The electrode can contain micro contacts for detailed data acquisition and is still thinner and softer than comparable products. CE approval is expected by the middle of this year.
Domain Therapeutics S.A. announced in january that Domain Therapeutics grants Prexton Therapeutics (Geneva – Switzerland) an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson's disease.
The chemical series was previously developed through a licensing and collaboration agreement signed between Domain and Merck Serono, a division of Merck (Darmstadt – Germany) in January 2011. This agreement between Domain Therapeutics and Prexton Therapeutics – a spin-off company of Merck Serono formed around its R&D portfolio in the field of Parkinson's disease – follows a strategic decision from Merck Serono to focus its research efforts on certain diseases such as multiple sclerosis, cancer and immunemediated diseases.
Under the terms of the agreement signed between Domain and Prexton, Prexton will benefit from an exclusive license option to progress the mGluR4 PAM drug candidates into clinical development.
The Centre européen d'étude du Diabète (CeeD) and its partners have just received nearly 5.5 million Euros for the co – funding of a European research project. It should lead to a first clinical validation of the bioartificial pancreas MAILPAN®, which prototype has been developed through two previous European projects, led by CeeD. Over a period of 36 months and called BIOSID, this project coordinated by the CeeD unites 7 partners from 3 different countries.
The ultimate goal of this project is to provide a solution to the main obstacles of human pancreatic transplants (islets of Langerhans or entire pancreas), which are immune rejection and the lack of matching donors.
The full consortium brings together 4 SMEs and 3 public research organizations, from three different countries (France, Belgium and United Kingdom), which will each have a role in the validation of the various stages of the project. The consortium's expertise includes encapsulation techniques, cellular, transplantation and formulation engineering as well as a clinical expertise.
BioValley promotes the cluster's companies with Venture Valuation / Biotechgate!
Venture Valuation is a Swiss based company specializing in independent assessments and valuations of high-growth companies in biotechnology, life sciences and medical technology. Clients include companies as well investors like family offices, corporate venture funds, venture capitalists and private investors. Company valuations are used for fundraising, M&A, fairness opinions and reporting. The product valuations main focus are in- and out-licensing as well as portfolio decisions. Furthermore, the company manages and runs the global Biotechgate Database (www.biotechgate.com) as a subscription service and a white label solution for organizations like BioValley, BIOTECanada, BioCom San Diego, Swiss Stock Exchange SIX, Swiss Biotech, BIO.NRW, Medicon Valley, SwedenBIO and over 20 other partners.
This entry was posted in Newsletters archives. Bookmark the permalink. Comments are closed, but you can leave a trackback: Trackback URL.